Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03018418 · ClinicalTrials.gov registry record · Phase 2

Proton Therapy in Reducing Toxicity in Anal Cancer

A Phase 2 study of Anus Neoplasms, sponsored by Jordan Kharofa.

Active
Registry status
Phase 2
Development phase
14
Enrollment target
1
Study location

NCT03018418 is a Phase 2 study of Anus Neoplasms that is active but no longer recruiting, run by Jordan Kharofa. The registered enrollment target is 14 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03018418, a Phase 2 study of Anus Neoplasms, is active but no longer recruiting, sponsored by Jordan Kharofa.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to determine whether the amount of radiation given to the normal areas around the anal cancer can be reduced by using Proton Therapy while reducing the side effects that are seen with standard therapy.

Conditions Studied

Interventions

  • DRUG Chemotherapy
  • RADIATION Proton therapy

Study Locations (1)

Ohio

  • UC Health - Cincinnati

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2017-01-04
Est. Completion 2025-07-01
Phase Phase 2

Sponsor

Jordan Kharofa

2 total trials

What the Registry Record Tells You About NCT03018418

The ClinicalTrials.gov registry entry for NCT03018418 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jordan Kharofa, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Anus Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Chemotherapy is the first listed.

NCT03018418 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT03018418 about?

NCT03018418 is a clinical study titled "Proton Therapy in Reducing Toxicity in Anal Cancer". The purpose of this research study is to determine whether the amount of radiation given to the normal areas around the anal cancer can be reduced by using Proton Therapy while reducing the side effects that are seen with standard therapy.

What is the current status of trial NCT03018418?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2017-01-04. Estimated completion is 2025-07-01.

What conditions does trial NCT03018418 study?

This clinical trial studies the following conditions: Anus Neoplasms.

What interventions are being tested in trial NCT03018418?

The interventions under investigation include: Chemotherapy (DRUG), Proton therapy (RADIATION).

Who is sponsoring clinical trial NCT03018418?

This trial is sponsored by Jordan Kharofa, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03018418 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anus Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.